MedTrace Logo

Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura

NCT05093257 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-10-26

No results posted yet for this study

Summary

Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by bleeding due to isolated thrombocytopenia with platelet count less than 100 × 109/L. ITP is classified based on course of disease into acute (3- \<12 months), and chronic (≥12 months). ITP usually has a chronic course in adults whereas approximately 80-90% of children undergo spontaneous remission within weeks to months of disease onset. The main pathogenesis of ITP is the loss of immune tolerance to platelet auto-antigens, which results in increased platelet destruction and impaired thrombopoiesis by autoantibodies and cytotoxic T lymphocytes (CTLs). Platelet autoantibodies, particularly antiglycoprotein (GP) GPIIbIIIa and anti-GPIbIX, are known to cause thrombocytopenia in patients with ITP. As a main component of cellular immunity, T cells play an important role in body defense and peripheral tolerance. Changing number and function of these cells is closely associated with various diseases, including ITP.NK cells can also modulate cellular immunity in ITP patients.

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DIAGNOSTIC_TEST

Laboratory investigations for control

1. Complete blood picture . 2. Erythrocyte sedimentation rate(ESR). 3. Liver function tests . 4. Kidney function tests. 5. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry

DIAGNOSTIC_TEST

Laboratory investigations for patients

1. Complete blood picture . 2. Erythrocyte sedimentation rate(ESR). 3. Liver function tests . 4. Kidney function tests. 5. Anti-nuclear antibodies test by immunoflourescence for ITP patients. 6. Bone marrow aspiration (for diagnosis of ITP). 7. CD3, CD4,CD8,CD16,CD56 from peripheral blood samples by Flowcytometry.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-11-30
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05093257 on ClinicalTrials.gov